Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash from Investing Activities (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Cash from Investing Activities for 14 consecutive years, with -$32000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 63.64% year-over-year to -$32000.0, compared with a TTM value of -$58000.0 through Dec 2025, up 89.57%, and an annual FY2025 reading of -$58000.0, up 89.57% over the prior year.
  • Cash from Investing Activities was -$32000.0 for Q4 2025 at Catalyst Pharmaceuticals, down from -$26000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$10000.0 in Q2 2024 and bottomed at -$162.4 million in Q1 2023.
  • Average Cash from Investing Activities over 5 years is -$21.8 million, with a median of -$165500.0 recorded in 2022.
  • The sharpest move saw Cash from Investing Activities crashed 70215.91% in 2023, then surged 99.88% in 2024.
  • Year by year, Cash from Investing Activities stood at -$41000.0 in 2021, then crashed by 221.95% to -$132000.0 in 2022, then crashed by 28928.79% to -$38.3 million in 2023, then skyrocketed by 99.77% to -$88000.0 in 2024, then soared by 63.64% to -$32000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for CPRX at -$32000.0 in Q4 2025, -$26000.0 in Q2 2025, and -$88000.0 in Q4 2024.